Sigma-Aldrich in the news

Michele Smith has been appointed Head of Global Quality Systems at MilliporeSigma, bringing over two decades of biopharmaceutical quality assurance and compliance leadership.

Sigma-Aldrich's employee count decreased by 2.1% from 4,241 in 2023 to 4,151 in 2026.

Honeywell acquired a German laboratory research chemicals business from Sigma-Aldrich for approximately 105 million euro.

Merck KGaA is acquiring Bio-Techne for $11.3 billion to expand its life science capabilities and product offerings.

Merck KGaA is acquiring life science tool provider Bio-Techne for $11.3 billion to expand its research and manufacturing capabilities.

Sigma-Aldrich provides scalable high-tech chemical products and custom manufacturing services for life science research and pharmaceuticals.

Sigma-Aldrich is expanding its life science and material offerings by adding Electroninks' high-precision gold and silver nanoparticle inks for advanced electronic and medical device manufacturing.

A new market research report analyzes growth drivers and competitive positioning for transfection reagents through 2033.

Sigma-Aldrich demonstrates strong financial health with consistent net income, significant free cash flow, and a shareholder-friendly approach through consistent share repurchases and dividends.

The HDAC2 Antibody Market is booming due to rising demand and continuous innovation, with significant growth projected from 2026 to 2033, driven by key players like BioLegend, Sigma-Aldrich, and R&D Systems.

Coherent Market Insights published a report forecasting rapid growth in the IHC Antibody Market from 2026 to 2033, detailing key trends, competitors, and strategic opportunities.

Coherent Market Insights has published a comprehensive report on the DNA Damaging Agents Market, detailing industry trends, growth opportunities, and major players for the forecast period of 2026-2033.

A new report forecasts significant growth in the Column RNA Extraction Market through 2033, analyzing trends, competition, and opportunities across various segments and regions.

The 2-Ethyl EDOT market is expanding due to rising demand for conductive polymers in electronics like OLED displays and solar cells, with Sigma-Aldrich playing a role in this growth.

Sigma-Aldrich is relocating its Milwaukee fine chemical plant to a new $52 million facility, funded in part by the sale of its current site for highway redevelopment.

Honeywell sold its Arklow, Ireland facility, which manufactured active pharmaceutical ingredients, to Sigma-Aldrich.

Sigma-Aldrich acquired Cell Marque, a company specializing in in vitro diagnostic antibody reagents and kits, to enhance its diagnostics offerings.

Sigma-Aldrich and genOway expanded their CRISPR/Cas9 strategic alliance to streamline patent licensing for rodent models and mammalian cell research.

Sigma-Aldrich and CVC have filed a series of preliminary motions and counter-motions in a CRISPR patent interference case, addressing issues of patentability, priority, and the scope of the invention.

Sigma-Aldrich was fined €7.5 million by the European Commission for withholding information about an innovation project during its merger review with Merck.